CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 1188413-1188594 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T32650","span":{"begin":0,"end":181},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Subsequent passive immunotherapy has shown similar changes (Bapineuzimab, Elan Pharmaceuticals) raising the possibility that it may be a generic complication of Abeta immunotherapy."}

    Epistemic_Statements

    {"project":"Epistemic_Statements","denotations":[{"id":"T2586","span":{"begin":0,"end":181},"obj":"Epistemic_statement"}],"text":"Subsequent passive immunotherapy has shown similar changes (Bapineuzimab, Elan Pharmaceuticals) raising the possibility that it may be a generic complication of Abeta immunotherapy."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T24","span":{"begin":0,"end":181},"obj":"Sentence"}],"text":"Subsequent passive immunotherapy has shown similar changes (Bapineuzimab, Elan Pharmaceuticals) raising the possibility that it may be a generic complication of Abeta immunotherapy."}